Results 211 to 220 of about 610,444 (251)
Some of the next articles are maybe not open access.
Engineered antibody fragments and the rise of single domains
Nature Biotechnology, 2005With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals. In fact, by 2008, engineered antibodies are predicted to account for >30% of all revenues in the biotechnology market. Smaller recombinant antibody fragments (for example,
Philipp, Holliger, Peter J, Hudson
openaire +2 more sources
Bispecific Single Domain Antibodies
2011Monoclonal antibodies are now widely recognized as therapeutic molecules and more than 25 molecules have been approved in the United States and other countries. Despite these successes, the clinical activity of these molecules is still far from optimal and new solutions have to be found, especially in the field of cancer therapy.
Patrick Chames, Daniel Baty
openaire +1 more source
Prospective Applications of Single-Domain Antibodies in Biomedicine
Molecular Biology, 2020Methods that utilize highly specific antibodies, anti-idiotypic antibodies, various recombinant molecules with antibody properties and immunocorrection and immunoprophylaxis with the help of vaccines are in demand and are intensely developed in the field of biomedicine.
openaire +2 more sources
2006
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source
Orally delivered single-domain antibodies against gastrointestinal pathogens
Trends in Biotechnology, 2023Andreas Hougaard Laustsen +2 more
exaly
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
Frontiers in Immunology, 2022Boris Naroditsky +2 more
exaly
Identification of Human Single-Domain Antibodies against SARS-CoV-2
Cell Host and Microbe, 2020Cheng Li, Shuai Xia, Jiang Shibo
exaly